Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) Stock Overview
Explore Bristol-Myers Squibb Company’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
96.7B
P/E Ratio
17.76
EPS (TTM)
$2.68
ROE
0.32%
BMY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Bristol-Myers Squibb Company (BMY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $42.06.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 17.76 and a market capitalization of 96.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Christopher S. Boerner
34,100
430 East 29th Street, Princeton, NY
1972